Search

Displaying results 1981 - 1990 of 3020 in total
  1. Drug

    Carboplatin

    go.drugbank.com/drugs/DB00958
    ApprovedInvestigational

    [A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]

    Products: BLASTOCARB RU, BLASTOCARB RU 450 MG (SOLUCION INYECTABLE)
  2. Target

    Cytochrome b-c1 complex subunit 9

    go.drugbank.com/bio_entities/BE0003861
    TargetHumans

    complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over

    Synonyms: Cytochrome c1 non-heme 7 kDa protein
  3. Drug

    3-Methylthiofentanyl

    go.drugbank.com/drugs/DB01439
    ExperimentalIllicit

    3-Methyl-thiofentanyl is a fentanyl analog and an opioid analgesic that works by inducing central nervous system (CNS) depression.

  4. Drug

    Socazolimab

    go.drugbank.com/drugs/DB18845
    Investigational

    Socazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-pd-l1 Antibody) in Patients With ES-SCLC).

  5. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. FX06 has proven safe in acute and subchronic toxicological st...

  6. Drug

    Talarozole

    go.drugbank.com/drugs/DB13083
    Investigational

    Talarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.

  7. Drug

    Etesevimab

    go.drugbank.com/drugs/DB15897
    Investigational

    [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179] … progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns.

  8. Drug

    Tigecycline

    go.drugbank.com/drugs/DB00560
    ApprovedInvestigational

    Food and Drug Administration (FDA) on June 17, 2005.

  9. Drug

    Carfilzomib

    go.drugbank.com/drugs/DB08889
    ApprovedInvestigational

    FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]

  10. Drug

    Ertugliflozin

    go.drugbank.com/drugs/DB11827
    ApprovedInvestigational

    [A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621]